Serum Institute of India to Manufacture Birsa-101
During Janjatiya Gaurav Utsav 2026, the Ministry of Tribal Affairs, CSIR and CSIR-IGIB held a workshop on Birsa-101, India’s first indigenous CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-based gene therapy for sickle cell disease. Named after Bhagwan Birsa Munda (150th birth anniversary), it was developed by CSIR-IGIB with ministry support; technology transferred to Serum Institute of India. It uses engineered enFnCas9 with up to 1,000-fold fewer off-target events, editing bone-marrow stem cells to correct the single mutation, aligning with India’s 2047 elimination goal in tribal belts.


